ESPERION THERAPEUTICS ($NASDAQ:ESPR) released its Q2 earnings report for the 2023 fiscal year on June 30th 2023. Revenue increased to USD 25.8 million, a 36.9% rise compared to the same quarter in the previous year. Net income decreased from -66.3 million to -49.9 million year-over-year.
The stock opened at $1.7 and closed at $1.7, representing a 7.6% increase from the previous closing price of $1.6. This increase in the company’s stock was largely due to positive news from the release of the earnings report. This news was well-received by investors as it showed signs of the company’s growth and stability over the past year.
Thus, it is no surprise that the stock saw a 7.6% increase in value following the release of these numbers. Looking ahead, ESPERION THERAPEUTICS is expected to continue to experience growth and stability as long as it continues to produce strong earnings reports. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Esperion Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Esperion Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Esperion Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Esperion Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Esperion Therapeutics Intrinsic Stock Value
At GoodWhale, we believe in helping people make informed decisions when it comes to investing in stocks. That’s why we have created a powerful financial analysis tool to assess the financials of ESPERION THERAPEUTICS. After running our analysis, we have determined that the intrinsic value of ESPERION THERAPEUTICS shares is around $3.9, based on our proprietary Valuation Line. This means that the current market price of $1.7 represents a 56.5% discount to its intrinsic value. This could be an opportunity for investors to buy ESPERION THERAPEUTICS shares at a discounted price. However, we always recommend doing your own research before investing in any stock to make sure it meets your financial goals. More…
Risk Rating Analysis
Star Chart Analysis
The competition among Esperion Therapeutics Inc, Intra-Cellular Therapies Inc, Redhill Biopharma Ltd, and Biofrontera Inc is fierce. Each company is vying for a share of the market for treatments for cholesterol and other lipid disorders. Each company has its own unique approach to treatment, and each has its own strengths and weaknesses. The competition among these companies is sure to be fierce, and the winner is likely to be the company that can best utilize its strengths and capitalize on its rivals’ weaknesses.
– Intra-Cellular Therapies Inc ($NASDAQ:ITCI)
As of 2022, Intra-Cellular Therapies Inc has a market cap of 4.38B and a Return on Equity of -26.73%. The company focuses on the development of drugs for the treatment of neuropsychiatric disorders.
– Redhill Biopharma Ltd ($NASDAQ:RDHL)
Redhill Biopharma Ltd is a biopharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastrointestinal and inflammatory diseases. The company’s market cap is 43.4M as of 2022 and its ROE is -2625.79%. The company’s products include RHB-104, RHB-105, and RHB-106. RHB-104 is in Phase III clinical trials for the treatment of Crohn’s disease and ulcerative colitis. RHB-105 is in Phase II clinical trials for the treatment of Helicobacter pylori infection. RHB-106 is in Phase I clinical trials for the treatment of inflammatory bowel disease.
The company’s market cap is $25.2 million and its ROE is -91.63%. Biofrontera is a pharmaceutical company that focuses on the development and commercialization of dermatological drugs. The company’s lead product is Ameluz, a prescription cream used to treat actinic keratosis, a precancerous skin condition. Biofrontera also markets two over-the-counter products: Effudix, a cream for the treatment of actinic keratosis, and Belixos, a gel for the treatment of superficial skin infections.
Esperion Therapeutics has released its Q2 earnings report for the 2023 fiscal year. Total revenue has seen an impressive 36.9% increase to USD 25.8 million, while net income was reported at -49.9 million, a decrease from the previous year. This news has had a positive impact on the company’s stock price on the same day, providing a positive signal for investors. Moving forward, investors should analyse Esperion’s financial performance, the company’s products and services, and potential risks associated with the stock before making an investment decision.